Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech's board met on February 13, 2026, and approved unaudited standalone and consolidated financial results for Q3 FY26 and the nine months ended December 31, 2025. On a standalone basis, Q3 PAT came in at Rs. 259.04 lakhs, up from Rs. 220.55 lakhs in the previous quarter and Rs. 252.27 lakhs a year ago, while 9M PAT slipped to Rs. 643.65 lakhs from Rs. 704.94 lakhs. Consolidated 9M PAT improved to Rs. 530.95 lakhs from Rs. 469.20 lakhs, with consolidated 9M EPS rising to Rs. 3.93 from Rs. 3.69. The statutory auditor (Rai Qimat & Associates) issued a clean limited review report with no qualifications. Two independent directors — Harish Pande and Arun Kumar — completed two consecutive 5-year terms and ceased to be directors at the close of business on February 13, 2026, leading to reconstitution of the Audit, Stakeholders Relationship, Nomination & Remuneration, Risk Management, and CSR committees.
Mixed picture: standalone nine-month profit softened year-on-year though consolidated profit improved, likely helped by subsidiaries. The exit of two long-serving independent directors is routine but could create short-term governance uncertainty until replacements are inducted.